Neurocrine Biosciences has agreed to acquire Soleno Therapeutics for $2.9 billion in cash, the companies announced, marking a major expansion into treatments for metabolic disorders.
Pfizer has signed a licensing agreement with China-based Sciwind Biosciences for its type 2 diabetes treatment ecnoglutide, in a deal that could generate up to $495 million in milestone payments.
06 Apr 2026-15:30
24 Feb 2026-10:18
